Extracellular and intracellular mechanisms that mediate the metastatic activity of exogenous osteopontin

Cancer

Volumn 115, Issue 8, 2009, Pages 1753-1764

  Mandelin, Jami ^a   Lin, Emme C K ^b   Hu, Dana D ^a   Knowles, Susan K ^b   Do, Kim Anh ^a   Wang, Xuemei ^a   Sage, E Helene ^c   Smith, Jeffrey W ^b   Arap, Wadih ^a,b   Pasqualini, Renata ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b BURNHAM INSTITUTE   (United States)

^c BENAROYA RESEARCH INSTITUTE   (United States)

Author keywords

c Src; Endothelium; Metastasis; Osteopontin

Indexed keywords

ACTIN; ALPHAVBETA5 INTEGRIN; ARGININE; ASPARTIC ACID; GLUTAMIC ACID; GLYCINE; HERMES ANTIGEN; OSTEOPONTIN; PROTEIN TYROSINE KINASE; TYROSINE; VITRONECTIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ADHESION; CONTROLLED STUDY; CYTOSKELETON; HUMAN; HUMAN CELL; LUNG METASTASIS; MELANOMA CELL; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEPHOSPHORYLATION; PROTEIN PHOSPHORYLATION; ROUS SARCOMA ONCOVIRUS; SARCOMA CELL; SIGNAL TRANSDUCTION; STRESS FIBER; VASCULAR ENDOTHELIUM;

ACTINS; ANIMALS; CELL ADHESION; CELL LINE, TUMOR; ENDOTHELIUM, VASCULAR; GENES, SRC; HUMANS; MELANOMA; MICE; MUTATION; NEOPLASM METASTASIS; OLIGOPEPTIDES; OSTEOPONTIN; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; SARCOMA; SIGNAL TRANSDUCTION;

EID: 65249177243     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24170     Document Type: Article

References (46)

1. Denhardt DT, Noda M, O'Regan AW, Pavlin D, Berman JS. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest. 2001;107:1055-1061.
2. Furger KA, Menon RK, Tuck AB, Bramwell VH, Chambers AF. The functional and clinical roles of osteopontin in cancer and metastasis. Curr Mol Med. 2001;1:621-632.
3. Rangaswami H, Bulbule A, Kundu GC. Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol. 2006;16:79-87.
4. Weber GF. The metastasis gene osteopontin: a candidate target for cancer therapy. Biochim Biophys Acta. 2001;1552:61-85.
5. Allan AL, George R, Vantyghem SA, et al. Role of the integrin-binding protein osteopontin in lymphatic metastasis of breast cancer. Am JPathol. 2006;169:233-246.
6. Bramwell VH, Doig GS, Tuck AB, et al. Serial plasma osteopontin levels have prognostic value in metastatic breast cancer. Clin Cancer Res. 2006;12:3337-3343.
7. Kang Y, Siegel PM, Shu W, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell. 2003;3:537-549.
8. Singhal H, Bautista DS, Tonkin KS, et al. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin Cancer Res. 1997;3:605-611.
9. Hotte SJ, Winquist EW, Stitt L, Wilson SM, Chambers AF. Plasma osteopontin: associations with survival and metastasis to bone in men with hormone-refractory prostate carcinoma. Cancer. 2002;95:506-512.
10. Ramankulov A, Lein M, Kristiansen G, Loening SA, Jung K. Plasma osteopontin in comparison with bone markers as indicator of bone metastasis and survival outcome in patients with prostate cancer. Prostate. 2006;67:330-340.
11. Ye QH, Qin LX, Forgues M, et al. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med. 2003;9:416-423.
12. Le QT, Sutphin PD, Raychaudhuri S, et al. Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res. 2003;9:59-67.
13. Oldberg A, Franzen A, Heinegard D. Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence. Proc Natl Acad Sci USA. 1986;83:8819-8823.
14. Bornstein P, Sage EH. Matricellular proteins: extracellular modulators of cell function. Curr Opin Cell Biol. 2002;14:608-616.
15. Xuan JW, Hota C, Chambers AF. Recombinant GST- human osteopontin fusion protein is functional in RGD- dependent cell adhesion. JCell Biochem. 1994;54:247-255.
16. Engvall E, Ruoslahti E. Binding of soluble form of fibro- blast surface protein, fibronectin, to collagen. Int J Cancer. 1977;20:1-5.
17. Morla A, Zhang Z, Ruoslahti E. Superfibronectin is a functionally distinct form of fibronectin. Nature. 1994;367:193-196.
18. Pasqualini R, Bourdoulous S, Koivunen E, Woods VL Jr, Ruoslahti E. A polymeric form of fibronectin has antimetastatic effects against multiple tumor types. Nat Med. 1996; 2:1197-1203.
19. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:157-481.
20. Pierschbacher MD, Ruoslahti E. Variants of the cell recognition site of fibronectin that retain attachment-promoting activity. Proc Natl Acad Sci USA. 1984;81:5985-5988.
21. Ruoslahti E. RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol. 1996;12:697-715.
22. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science. 1998;279:377-380.
23. Assa-Munt N, Jia X, Laakkonen P, Ruoslahti E. Solution structures and integrin binding activities of an RGD peptide with 2 isomers. Biochemistry. 2001;40:2373-2378.
24. Hajitou A, Trepel M, Lilley CE, et al. A hybrid vector for ligand-directed tumor targeting and molecular imaging. Cell. 2006;125:385-398.
25. Koivunen E, Wang B, Ruoslahti E. Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrins. Biotechnology (N Y). 1995;13:265-270.
26. Pasqualini R, Koivunen E, Ruoslahti E. Alpha v integrins as receptors for tumor targeting by circulating ligands. Nat Biotechnol. 1997;15:542-546.
27. Faure S, Salazar-Fontana LI, Semichon M, et al. ERM proteins regulate cytoskeleton relaxation promoting T cell-APC conjugation. Nat Immunol. 2004;5:272-279.
28. Dustin ML, Cooper JA. The immunological synapse and the actin cytoskeleton: molecular hardware for T cell signaling. Nat Immunol. 2000;1:23-29.
29. Linder S, Aepfelbacher M. Podosomes: adhesion hot-spots of invasive cells. Trends Cell Biol. 2003;13:376-385.
30. Tang H, Hao Q, Rutherford SA, Low B, Zhao ZJ. Inactivation of SRC family tyrosine kinases by reactive oxygen species in vivo. J Biol Chem. 2005;280:23918-23925.
31. Ito T, Hashimoto Y, Tanaka E, et al. An inducible short-hairpin RNA vector against osteopontin reduces metastatic potential of human esophageal squamous cell carcinoma in vitro and in vivo. Clin Cancer Res. 2006;12:1308-1316.
32. Shevde LA, Samant RS, Paik JC, et al. Osteopontin knockdown suppresses tumorigenicity of human metastatic breast carcinoma, MDA-MB-435. Clin Exp Metastasis. 2006;23:123-133.
33. Suzuki M, Mose E, Galloy C, Tarin D. Osteopontin gene expression determines spontaneous metastatic performance of orthotopic human breast cancer xenografts. Am J Pathol. 2007;171:682-692.
34. McAllister SS, Gifford AM, Greiner AL, et al. Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell. 2008;133:994-1005.
35. Katagiri YU, Sleeman J, Fujii H, et al. CD44 variants but not CD44s cooperate with beta1-containing integrins to permit cells to bind to osteopontin independently of argi- nine-glycine-aspartic acid, thereby stimulating cell motility and chemotaxis. Cancer Res. 1999;59:219-226.
36. Humphries MJ, Olden K, Yamada KM. A synthetic peptide from fibronectin inhibits experimental metastasis of murine melanoma cells. Science. 1986;233:467-470.
37. Morris VL, Schmidt EE, Koop S, et al. Effects of the disin- tegrin eristostatin on individual steps of hematogenous metastasis. Exp Cell Res. 1995;219:571-578.
38. Trikha M, De Clerck YA, Markland FS. Contortrostatin, a snake venom disintegrin, inhibits beta 1 integrin-mediated human metastatic melanoma cell adhesion and blocks experimental metastasis. Cancer Res. 1994;54:4993-4998.
39. Lin YH, Yang-Yen HF. The osteopontin-CD44 survival signal involves activation of the phosphatidylinositol 3-kinase/Akt signaling pathway. J Biol Chem. 2001;276:46024-46030.
40. Teramoto H, Castellone MD, Malek RL, et al. Autocrine activation of an osteopontin-CD44-Rac pathway enhances invasion and transformation by H-RasV12. Oncogene. 2005;24:489-501.
41. Weber GF, Ashkar S, Glimcher MJ, Cantor H. Receptor- ligand interaction between CD44 and osteopontin (Eta-1). Science. 1996;271:509-512.
42. Khan SA, Cook AC, Kappil M, et al. Enhanced cell surface CD44 variant (v6, v9) expression by osteopontin in breast cancer epithelial cells facilitates tumor cell migration: novel post-transcriptional, post-translational regulation. Clin Exp Metastasis. 2005;22:663-673.
43. Crawford HC, Matrisian LM, Liaw L. Distinct roles of osteopontin in host defense activity and tumor survival during squamous cell carcinoma progression in vivo. Cancer Res. 1998;58:5206-5215.
44. Hruska KA, Rolnick F, Huskey M, Alvarez U, Cheresh D. Engagement of the osteoclast integrin alpha v beta 3 by osteopontin stimulates phosphatidylinositol 3-hydroxyl ki- nase activity. Endocrinology. 1995;136:2984-2992.
45. Das R, Mahabeleshwar GH, Kundu GC. Osteopontin induces AP-1-mediated secretion of urokinase-type plasminogen activator through c-Src-dependent epidermal growth factor receptor transactivation in breast cancer cells. J Biol Chem. 2004;279:11051-11064.
46. Chellaiah M, Fitzgerald C, Alvarez U, Hruska K. c-Src is required for stimulation of gelsolin-associated phosphatidyl-inositol 3-kinase. J Biol Chem. 1998;273:11908-11916.